DDDirk Dressler

Dirk Dressler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dirk Dressler has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Folate bioavailability in reconstructed skin models and effects of folate in a monolayer wound healing assay. Approaches on topic application

    by Dirk Dressler, Martin Ulmann, Gerd Wiesler

    In chronic and degenerative diseases impacting the skin folates play an important metabolic role improving wound healing and reducing skin irritations. In contrast to systemic folate administration little is known on skin penetration of folates after topical application. Here the penetration of simple aqueous solutions of reduced folates have been investigated with in-vitro reconstructed skin models mimicking the barrier of native human skin. For up to 24 h, penetration of the epidermis by newly developed folate salts and formulations were investigated. Aqueous and lipophilic solutions of L-formyltetrahydrofolate and L-mefolinate salts were able to penetrate the epidermis. Even more importantly, the skin model revealed the metabolic conversion of L-folinate to L-methyltetrahydrofolate. Exemplarily the effects of these new folate salts have been tested on wound healing in a scratch assay with primary human keratinocytes. All folates applied were able to enhance wound healing compared to the control. Bioavailability, metabolic conversion and physiologic effectiveness of new folate formulation have been shown successfully in in vitro applications providing evidence for the potent applicability of the new folates in preparations for topic application.

  • Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy

    by Uwe Walter, Christopher Mühlenhoff, Reiner Benecke, Dirk Dressler, Eilhard Mix, Janes Alt, Matthias Wittstock, Ales Dudesek, Alexander Storch, Christoph Kamm

    Objective To investigate the risk factors of neutralizing antibody (NAB)–induced complete secondary treatment failure (cSTF) during long-term botulinum neurotoxin (BoNT) treatment in various neurologic indications. Methods This monocenter retrospective cohort study analyzed the data of 471 patients started on BoNT therapy between 1995 and 2015. Blood samples of 173 patients were investigated for NABs using the mouse hemidiaphragm test (93 with suspected therapy failure, 80 prospective study participants). The frequency of NAB-cSTF was assessed for various indications: hemifacial spasm, blepharospasm, cervical dystonia, other dystonia, and spasticity. A priori defined potential risk factors for NAB-cSTF were evaluated, and a stepwise binary logistic regression analysis was performed to identify independent risk factors. Results Treatment duration was 9.8 ± 6.2 years (range, 0.5–30 years; adherence, 70.6%) and number of treatment cycles 31.2 ± 22.5 (3–112). Twenty-eight of 471 patients (5.9%) had NAB-cSTF at earliest after 3 and at latest after 103 treatment cycles. None of the 49 patients treated exclusively with incobotulinumtoxinA over 8.4 ± 4.2 (1–14) years developed NAB-cSTF. Independent risk factors for NAB-cSTF were high BoNT dose per treatment, switching between onabotulinumtoxinA and other BoNT formulations (except for switching to incobotulinumtoxinA), and treatment of neck muscles. Conclusions We present a follow-up study with the longest duration to date on the incidence of NAB-cSTF in patients treated with various BoNT formulations, including incobotulinumtoxinA. Whereas the overall risk of NAB-cSTF is low across indications and BoNT formulations, our findings underpin the recommendations to use the lowest possible dose particularly in cervical dystonia, and to avoid unnecessary switching between different formulations.


  • Open Access

    Identification of Shiga-Toxigenic Escherichia coli outbreak isolates by a novel data analysis tool after matrix-assisted laser desorption/ionization time-of-flight mass spectrometry

    by Martin Christner, Dirk Dressler, Mark Andrian, Claudia Reule, Orlando Petrini

    The fast and reliable characterization of bacterial and fungal pathogens plays an important role in infectious disease control and tracking of outbreak agents. DNA based methods are the gold standard for epidemiological investigations, but they are still comparatively expensive and time-consuming. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is a fast, reliable and cost-effective technique now routinely used to identify clinically relevant human pathogens. It has been used for subspecies differentiation and typing, but its use for epidemiological tasks, e. g. for outbreak investigations, is often hampered by the complexity of data analysis. We have analysed publicly available MALDI-TOF mass spectra from a large outbreak of Shiga-Toxigenic Escherichia coli in northern Germany using a general purpose software tool for the analysis of complex biological data. The software was challenged with depauperate spectra and reduced learning group sizes to mimic poor spectrum quality and scarcity of reference spectra at the onset of an outbreak. With high quality formic acid extraction spectra, the software’s built in classifier accurately identified outbreak related strains using as few as 10 reference spectra (99.8% sensitivity, 98.0% specificity). Selective variation of processing parameters showed impaired marker peak detection and reduced classification accuracy in samples with high background noise or artificially reduced peak counts. However, the software consistently identified mass signals suitable for a highly reliable marker peak based classification approach (100% sensitivity, 99.5% specificity) even from low quality direct deposition spectra. The study demonstrates that general purpose data analysis tools can effectively be used for the analysis of bacterial mass spectra.


  • In Vitro Activation of eNOS by Mangifera indica (Careless™) and Determination of an Effective Dosage in a Randomized, Double-Blind, Human Pilot Study on Microcirculation

    by Alexandra Gerstgrasser, Sigrid Röchter, Dirk Dressler, Christiane Schön, Claudia Reule, Sybille Buchwald-Werner

    Mangifera indica fruit preparation (Careless™) activates the evolutionary conserved metabolic sensors sirtuin 1 and adenosine monophosphate-activated protein kinase, which have been identified as playing a key role in microcirculation and endothelial function. Here, an acute effect of a single dose of 100 mg or 300 mg Careless™ on microcirculation was investigated in a randomized, double-blind, crossover pilot study in ten healthy women to determine the effective dosage. Microcirculation and endothelial function were assessed by the Oxygen-to-see system and pulse amplitude tonometry (EndoPAT™), respectively. Cutaneous blood flow was increased over time by 100 mg (54 % over pre-values, p = 0.0157) and 300 mg (35 % over pre-value, p = 0.209) Careless™. The EndoPAT™ reactive hyperemia response was slightly improved 3 h after intake compared to pretesting with 300 mg Careless™. Furthermore, activation of endothelial nitric oxide synthase, as an important regulator for endothelial function, was tested in vitro in primary human umbilical vein endothelial cells. Careless™, after simulation of digestion, increased the activated form of endothelial nitric oxide synthase dose-dependently by 23 % (300 µg/mL), 42 % (1500 µg/mL), and 60 % (3000 µg/mL) compared to the untreated control. In conclusion, the study suggests moderate beneficial effects of Careless™ on microcirculation, which is at least partly mediated by endothelial nitric oxide synthase activation.


  • Antientzündliche Wirkung einer Hyaluronsäure-Chondroitinsulfat-Präparation im In-vitro-Blasenmodell

    by A. Schulz, A.-M. Vestweber, D. Dressler

    Fragestellung: Die interstitielle Zystitis und BPS (bladder pain syndrome) [ 1 ] [ 2 ] sind chronisch-entzündliche Erkrankungen der Blase. Es handelt sich um bis heute nicht völlig geklärte Erkrankungen deren Ursache, wie auch die der chronisch ­rezidivierenden Zystitidien in einer Schädigung der Glycosaminoglycanschicht (GAG-Schicht) des Blasenepithels liegen könnte [ 3 ]. Zur Linderung der Symptome und als Schutz des Blasenepithels werden hyaluronsäurehaltige Präparate angewandt [ 4 ] [ 5 ] [ 6 ] [ 7 ]. Ziel der hier beschriebenen Arbeiten war die Prüfung der Verträglichkeit und der antientzündlichen Wirksamkeit eines solchen, gegen BPS gerichteten Präparats, welches neben Hyaluronsäure auch Chondroitinsulfat enthält. Methode: Als In-vitro-Modell des Blasenepithels wurde die Urothelzelllinie T24 eingesetzt, da sie auf entsprechende Stimuli mit der Ausschüttung von Entzündungsmarkern, hier Interleukin 6 (IL-6) reagieren kann [ 8 ]. Die Zellen wurden mit der Präparation behandelt, anschließend wurde TNFα zur Induktion der Entzündung appliziert und der Grad der Entzündungsreaktion anhand der Ausschüttung von IL-6 im Vergleich zu Kontrollkulturen bestimmt. Ergebnisse: Die Behandlung der Zellen mit Hyaluronsäure und Chondroitinsulfat reduzierte die durch TNFα induzierte IL-6-Ausschüttung. Dieses Ergebnis zeigt eine antiinflammatorische Wirkung des Präparats an. Darüber hinaus wurde durch die Ermittlung der Zahl lebender Zellen nach Behandlung mit dem Präparat eine hohe Toleranz der Zellen gegenüber der Testsubstanz, selbst in hohen Konzentrationen, bestimmt. Diese Daten lassen auf eine gute Verträglichkeit in der Anwendung schließen. Schlussfolgerung: Die vorliegenden Ergebnisse lassen den Einsatz des Präparates für die Therapie der interstitiellen Zystitis bzw. der chronisch-rezidivierenden Zystidien viel versprechend erscheinen. Die vorliegende Arbeit demonstriert erneut die Anwendbarkeit des Zellkulturmodells für die Prüfung neuer Therapieansätze. Purpose: Interstitial cystitis and BPS (bladder pain syndrome) [ 1 ] [ 2 ] are chronic inflammatory diseases of the bladder. They are as yet imper­fectly understood diseases, possibly originating from damage to the glycosaminoglycan layer of the bladder epithelium [ 3 ]. Hyaluronic acid-containing preparations are currently utilised for palliation of the symptoms and protection of the bladder epithelium [ 4 ]. The aim of the work ­de­scribed here was the evaluation of one of these preparations containing chondroitin sulfate to­gether with hyaluronic acid. Material and Methods: The preparation was evaluated for its anti-inflammatory potential as well as regarding the tolerance by the bladder epithelium. The urothelial cell line T24 was employed as an in vitro model of the human bladder because of its ability to react to adequate stimuli with the release of interleukin 6. To this end the cells were treated with hyaluronic acid and chondroitin sulfate. Subsequently, TNF-α was applied to induce inflammation. The severity of inflammation was measured on the basis of the IL-6 released by the cells in comparison to untreated control cultures. Results: A reduction of TNF-α-induced IL-6 release after treatment with hyaluronic acid and chondroitin sulfate was observed, indicating the anti-inflammatory action of the preparation. As shown by the large number of living cells after treatment the test preparation did not affect cell viability even in high concentrations. These data suggest a good tolerance of the product by the patients. Conclusion: The administration of the preparation in patients suffering from interstitial cystitis or BPS appears promising. In additional, the presented work demonstrates the feasibility of the cell culture model for the screening of new therapeutic approaches.


  • Verbessertes Modell der humanen katheterisierten Blase für das Screening antibakteriell wirksamer Agenzien

    by A. Schulz, A.-M. Vestweber, W. Leis, D. Stark, D. Dressler

    Fragestellung: Verkrustung und damit einhergehende Blockierung von Kathetern durch kristalline Biofilme des Bakterienstammes Proteus mirabilis stellt eine häufig vorkommende Komplikation bei Patienten mit Langzeitblasenkathetern dar. In der vorliegenden Arbeit wurde am Beispiel von Triclosan geprüft, ob ein neues, dem physiologischen Vorbild Blase ähnliches Modell in der Lage ist, positive Wirkungen von Bakteriziden und Bakteriostatika nachzuweisen. Material und Methode: Als Modell der menschlichen Blase dienten sterile Infusionsbeutel, in deren Zuführung die Katheter eingeführt wurden. Der über einen weiteren Zugang zugeführte künstliche Urin wurde mit einem typischen Vertreter blaseninfizierender Mikroorganismen (Proteus mirabilis) beimpft. Im Abstand von ca. 24 h wurden die Keimzahl und der pH-Wert im künstlichen Urin sowie die Verstopfung der Katheter kontrolliert und dokumentiert. Das Lumen der Katheter wurde nach Abschluss des Prüfzeitraums elektronenmikroskopisch untersucht. Ergebnisse: Durch die eingesetzten Triclosanblockerlösungen wurden die untersuchten Katheter im Gegensatz zur Plazebolösung über den gesamten Prüfungszeitraum frei gehalten. Der pH-Wert innerhalb des Models stieg maximal bis zum kritischen Wert von pH 7 und die Keimzahlen lagen nahezu konstant um den Wert der Ausgangskeimzahl. Schlussfolgerung: Triclosan diffundiert im gewählten Model über die Katheterballons in den künstlichen Urin und ist in der Lage, im Gegensatz zur Plazebozubereitung, das Wachstum von Proteus mirabilis über eine bestimmte Zeit zu hemmen und damit einen pH-Wert Anstieg sowie die Bildung eines kristallinen Biofilms im künstlichen Urin zu verhindern. Die Anwendbarkeit dieses neuen Modells als Blasenmodell konnte somit belegt werden. Purpose: Catheter encrustation and associated blockage by a crystalline Proteus mirabilis biofilm constitute a continuous problem in long-term catheterised patients. The objective of the present work was to verify a new, physiological bladder model possessing the ability to show that triclosan-blocking solutions exert bactericidal and bacteriostatic activities. Material and Methods: Catheterised sterile infusion bags served as human bladder models. Artificial urine inoculated with Proteus mirabilis was administered by a further aperture. Samples for measurement of pH value and microbial count were collected at intervals of 24 h. Upon completion of testing catheter encrustation was assessed and visualised by scanning electron microscopy. Results: In contrast to the application of placebo solution, in models filled with triclosan-blocking solution the catheters drained freely for the experimental period. Similar results were obtained for pH values and microbial count. The pH of the artificial urine did not exceed a critical value of pH 7 and the numbers of organisms correspond approximately to the initially inoculated number of organisms. Conclusion: In the model developed here, triclosan inhibits the growth of Proteus mirabilis over the test period by diffusing into the artificial urine through the catheter balloon. Thus, triclosan acts against the pH increase as well as the formation of a crystalline biofilm. Taken together, the adaptability of this new, physiological model of the human bladder could be shown.


  • The Application of Normal, SV40 T-antigen-immortalised and Tumour-derived Oral Keratinocytes, under Serum-free Conditions, to the Study of the Probability of Cancer Progression as a Result of Environmental Exposure to Chemicals

    by Rebecca Ceder, Marina Merne, Claudia A. Staab, Jan Anders Nilsson, Jan-Olov Höög, Dirk Dressler, Karin Engelhart, Roland C. Grafström

    In vitro models are currently not considered to be suitable replacements for animals in experiments to assess the multiple factors that underlie the development of cancer as a result of environmental exposure to chemicals. An evaluation was conducted on the potential use of normal keratinocytes, the SV40 T-antigen-immortalised keratinocyte cell line, SVpgC2a, and the carcinoma cell line, SqCC/Y1, alone and in combination, and under standardised serum-free culture conditions, to study oral cancer progression. In addition, features considered to be central to cancer development as a result of environmental exposure to chemicals, were analysed. Genomic expression, and enzymatic and functional data from the cell lines reflected many aspects of the transition of normal tissue epithelium, via dysplasia, to full malignancy. The composite cell line model develops aberrances in proliferation, terminal differentiation and apoptosis, in a similar manner to oral cancer progression in vivo. Transcript and protein profiling links aberrations in multiple gene ontologies, molecular networks and tumour biomarker genes (some proposed previously, and some new) in oral carcinoma development. Typical specific changes include the loss of tumour-suppressor p53 function and of sensitivity to retinoids. Environmental agents associated with the aetiology of oral cancer differ in their requirements for metabolic activation, and cause toxic effects to cells in both the normal and the transformed states. The results suggest that the model might be useful for studies on the sensitivity of cells to chemicals at different stages of cancer progression, including many aspects of the integrated roles of cytotoxicity and genotoxicity. Overall, the properties of the SVpgC2a and SqCC/Y1 cell lines, relative to normal epithelial cells in monolayer or organotypic culture, support their potential applicability to mechanistic studies on cancer risk factors, including, in particular, the definition of critical toxicity effects and dose–effect relationships.


  • Expression of retinoid-related genes in serum-free cultures of normal, immortalized and malignant human oral keratinocytes.

    by D. Dressler, Z. Sarang, Z. Szondy, K. Engelhart, R. C. Grafstrom

    Retinoids are used in the clinical treatment of oral squamous carcinoma, including both early and late stages. Inter-individual variation in responsiveness, including a common insensitivity of advanced stages, suggest that changes in retinoid-related functions might characterize tumor development. To investigate a genetic basis for this hypothesis, an in vitro multi-step model of carcinogenesis involving normal (NOK), SV40 T antigen-immortalized (SVpgC2a) and malignant (SqCC/Y1) oral keratinocytes was analysed under identical culture conditions using micro-array technique (Affymetrix HG_U95A chip) for expression of 52 genes related to retinoid metabolism and actions. The variable detection of between 22-26 transcripts in the cell lines, involving binding/transport factors, receptors, transcriptional activators/repressors and responsive genes, indicated specificity in regards to the expression of known retinoid-related genes in oral keratinocytes. The transformed cell lines variably exhibited differences as compared to NOK, i.e., lower transcript levels for cellular retinol binding protein, the cellular retinoic acid binding protein II (CRABP II) and retinoic acid receptor gamma, whereas in contrast, the levels of CRABP I were higher. Transcripts for proteins interacting with nuclear retinoid receptors were similarly expressed among the cell types, whereas transcripts for retinoid-metabolizing enzymes were generally not detected. Finally, transcripts of retinoid-responsive genes, including RARRES3, RI58, NN8-4AG and midkine, were variably expressed. The overall results imply selective expression of retinoid-related functions in normal and transformed keratinocytes, and that cell transformation can impair the capacity for binding and storage of retinol as well as retinoic acid-mediated signalling. These multiple alterations are consistent with possible retinoid insensitivity during oral carcinogenesis.